ABBISKO-B (02256.HK): Presents CDK4 Inhibitor ABSK192 Data at ENA
NewTimeSpace News: On 19 November 2026, Abbisko Medicine Co., Ltd. (stock code: 2256) announced on a voluntary basis that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., presented preclinical data for its independently developed novel selective CDK4 inhibitor ABSK192 as a poster at the 38th EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics in 2026. The study was selected for the Late-Breaking Abstracts programme, and Dr Zhang Nannan, senior director of translational medicine and biomarker research, presented ABSK192's single-agent activity and broad combination potential in HR+/HER2- breast cancer models.
Results showed that ABSK192 has potent inhibitory activity against CDK4, with over 70-fold selectivity for CDK4 over CDK6. In HR+/HER2- breast cancer cell models, the drug showed significant antiproliferative activity and induced G1 cell-cycle arrest regardless of PIK3CA mutation status, while in vivo studies demonstrated significant antitumour activity as a single agent.
In combination studies, ABSK192 showed synergy with endocrine therapies fulvestrant and imlunestrant, PI3K inhibitors GDC-0077 and RLY-2608, and CDK2 inhibitor PF-07104091 across multiple cell models. ABSK192 is currently in preparation for IND submission.
The company said it cannot guarantee that ABSK192 will ultimately be successfully marketed and advised shareholders and potential investors to exercise caution when dealing in its shares.
- ABBISKO-B (02256.HK): Chairman Xu Yaochang Raises Stake to 11.26%
- ABBISKO-B (02256.HK): PIMJETMI wins FDA approval for TGCT, fourth marketing approval, US$20 million milestone
- ABBISKO-B (02256.HK) :renamed Abbisko Medicine Co., Ltd.
- ABBISKO-B (02256.HK): Lavengratinib wins EMA orphan status for ACH
- ABBISKO-B (02256.HK): Lavengratinib shows positive interim Phase II results in achondroplasia